Loading
Life sciences · Journal article
Russian Journal of Cardiology · September 23, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Aim. To assess the incidence of chronic kidney disease (CKD) in adult patients with hypertension (HTN) and markers of CKD without concomitant diabetes and symptomatic heart failure, as well as to describe the clinical and demographic characteristics and treatment options in the overall cohort and a subgroup with verified CKD. Material and methods. PRIORITY-CKD is a multicenter, observational, prospective study with a retrospective analysis of patients with hypertension and markers of CKD in the Russian Federation. The study design has been described in detail previously. Results. The analytical cohort included 9914 patients. The diagnosis of CKD was confirmed in 8430 (85%) patients with HTN and CKD markers during the study as follows: 3795 (38,3%) at Visit 1 and 4635 (46,8%) at Visit 2. The estimated glomerular filtration rate was used as diagnostic criteria in 8406 (97,4%) cases. Albuminuria/proteinuria and a combination of markers were used in 13 (0,2%) and 11 (0,1%) patients, respectively. In the overall cohort and the subgroup with verified CKD, women predominated, the median duration of hypertension was similar and amounted to 10 years. More than half of the patients had stage III hypertension and the very high cardiovascular risk category. A high frequency of metabolic risk factors (overweight, abdominal obesity, dyslipidemia) and coronary artery disease (33%/34,9% in the two cohorts, respectively) was observed. Uncontrolled blood pressure (BP) (systolic BP ≥140 and/or diastolic BP ≥90 mm Hg while receiving antihypertensive therapy (AHT)) and signs of AHT resistance were detected in 36,0% and 6,0% of patients in the overall cohort, respectively, and in the same proportion of patients in the CKD subgroup. Combination AHT was received by 72,3% of patients in the study cohort after Visit 1. After CKD diagnosis was confirmed, sodium-glucose cotransporter type 2 inhibitors were prescribed in 31,1% of cases. Conclusion. In the Russian population, CKD was confirmed in 85% of patients with HTN and CKD markers. Albuminuria/proteinuria was assessed extremely rarely. A high frequency of uncontrolled HTN, a significant burden of metabolic risk factors, and cardiovascular disease were observed in the overall cohort and the CKD subgroup. The incremental use of renoprotective therapy after verification of the CKD diagnosis was insufficient.